MDX Shares Mindax Limited
ASX · ASXLast in our picks 2026-09-25 — not in the current list; analysis below is from that screen
Stem-cell optionality and event-driven catalysts offer meaningful rerating potential.
Signal breakdown
- ▸Clinical and commercial catalysts keep sentiment constructive.
- ▸Above 50-day MA (+1.69%)
- ▸Above 200-day MA — long-term uptrend
Is MDX a buy right now?
Trend: MDX is trading below the 50-day average (-12.50%), RSI 23 — oversold territory, with a 3-month return of +40.00%.
Valuation & quality: Mindax Limited trades on price-to-book 3.89; fundamentals show net margin 0.0%, return on equity -6.4%, revenue growth 4.3% year on year.
Our screen: BUY (score 3) — Stem-cell optionality and event-driven catalysts offer meaningful rerating potential.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| -25.00% | -33.30% | +0.00% | +0.00% | +50.00% | +33.30% | +0.00% | +0.00% |
Fundamentals
Technical signals
About Mindax Limited
Mindax Limited engages in the exploration and development of mineral properties in Australia. The company operates in two segments, Gold and Iron Ore.
Sector: Basic Materials · Industry: Gold · Australia · Website
Related Health Care picks
Browse: all ASX stocks · Health Care picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.